Trousseau综合征的研究进展  

Progress of Trousseau Syndrome Studies

作　　者：程雪娇[1] 伊然[2] 董齐[1] 张歌[1] 关爽[1] 苑春兰 杨东梅 高青青[2] 方星薪 丁莹莹 CHENG Xue-jiao;YI Ran;DONG Qi;ZHANG Ge;GUAN Shuang;YUAN Chun-lan;YANG Dong-mei;GAO Qing-qing;FANG Xing-xin;DING Ying-ying(Department of Neurology,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Endocrine,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院神经内科,哈尔滨150001 [2]哈尔滨医科大学附属第一医院内分泌科,哈尔滨150001

出　　处：《中国临床神经科学》2019年第1期90-97,112,共9页Chinese Journal of Clinical Neurosciences

基　　金：国家自然科学基金(编号:81500912);黑龙江省自然科学基金(编号:H2015059);黑龙江省青年科学基金(编号:QC2011C117)

摘　　要：在恶性肿瘤患者中存在2%～5%动脉血栓形成。Trousseau综合征包括恶性肿瘤患者因凝血和纤溶机制异常而在其发病过程中出现的所有临床表现。目前认为Trousseau综合征所致缺血性脑卒中的主要发病机制是恶性肿瘤存在使凝血系统与纤溶系统之间失衡所致的高凝状态。其主要临床特点包括D-二聚体、肿瘤标志物水平明显升高,以及累及多血管分布区的MR多发弥散加权成像(DWI)高信号表现。主要治疗手段是抗肿瘤治疗及抗凝治疗,溶栓治疗的安全性和有效性仍存在一定争议。There are 2% to 5% of arterial thrombosis in patients with malignant tumors. Currently,Trousseau syndrome includes all clinical manifestations of malignant tumors in the course of their onset due to abnormal blood coagulation and fibrinolysis mechanisms. It is currently believed that the main pathogenesis of ischemic stroke caused by Trousseau syndrome is a hypercoagulable state caused by the imbalance between the coagulation system and the fibrinolytic system. The main clinical features include a significant increase in D-dimer levels and marked elevation of tumor markers,and multiple diffuse weighted imaging( DWI) high-signal performance involving multiple blood vessel distribution areas. The main treatment for Trousseau syndrome is anti-tumor therapy and anticoagulant therapy. The safety and efficacy of thrombolytic therapy remains controversial.

关 键 词：TROUSSEAU综合征 缺血性脑卒中 恶性肿瘤 高凝 D-二聚体 肿瘤标志物 

分 类 号：R743[医药卫生—神经病学与精神病学] R730.246[医药卫生—临床医学]